L., Gawarammana, I., Wood, D
6 Conclusion Within the conventionally defined normal range, the doseresponse relationships of different lipid components in metabolic and endocrine diseases may display a certain degree of specificity, and these patterns may be jointly influenced by shared pathophysiological processes, such as inflammation and oxidative stress, as well as by tissue-specific regulatory mechanisms
Potential direct anti-inflammatory mechanisms from preclinical and early clinical studies include: Modulation of immune cell function : GLP-1 receptor activation may reduce pro-inflammatory cytokine production from macrophages and other immune cells Reduction of oxidative stress : These medications may decrease reactive oxygen species production, which contributes to inflammatory processes Endothelial protection : GLP-1 receptor agonists may improve endothelial function and reduce vascular inflammation Inhibition of inflammatory signalling pathways : Including suppression of nuclear factor-kappa B (NF-B), a key regulator of inflammatory gene expression It's important to note that many of these mechanisms have been primarily demonstrated in laboratory or animal studies, with more limited evidence in humans
However, the most important key for successful treatment would be the presence of optimally activated T cells in tumor microenvironment with controlled ROS activity which may represent fruitful ground for long-term molecular anticancer strategies
Hawkley LC, Cacioppo JT
